Crossvault Capital Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | $13.6M | Sell |
88,555
-4,288
| -5% | -$655K | 5.34% | 3 |
|
|
2022
Q1 | $15.1M | Buy |
92,843
+380
| +0.4% | +$55.2K | 4.85% | 3 |
|
|
2021
Q4 | $12.5M | Buy |
92,463
+2,798
| +3% | +$331K | 3.76% | 7 |
|
|
2021
Q3 | $9.67M | Buy |
89,665
+14,175
| +19% | +$1.62M | 3.04% | 11 |
|
|
2021
Q2 | $8.78M | Buy |
75,490
+4,628
| +7% | +$521K | 2.68% | 16 |
|
|
2021
Q1 | $7.67M | Buy |
70,862
+675
| +1% | +$72.2K | 2.73% | 17 |
|
|
2020
Q4 | $7.52M | Buy |
70,187
+3,192
| +5% | +$307K | 2.8% | 16 |
|
|
2020
Q3 | $5.87M | Buy |
66,995
+3,743
| +6% | +$352K | 2.55% | 15 |
|
|
2020
Q2 | $6.21M | Buy |
63,252
+5,655
| +10% | +$498K | 2.88% | 13 |
|
|
2020
Q1 | $4.39M | Buy |
57,597
+18,705
| +48% | +$1.59M | 2.46% | 17 |
|
|
2019
Q4 | $3.44M | Buy |
38,892
+23,260
| +149% | +$1.93M | 1.51% | 25 |
|
|
2019
Q3 | $1.18M | Hold |
15,632
| – | – | 0.56% | 36 |
|
|
2019
Q2 | $1.14M | Hold |
15,632
| – | – | 0.56% | 36 |
|
|
2019
Q1 | $1.26M | Hold |
15,632
| – | – | 0.65% | 35 |
|
|
2018
Q4 | $1.44M | Buy |
15,632
+5,200
| +50% | +$457K | 0.82% | 33 |
|
|
2018
Q3 | $987K | Hold |
10,432
| – | – | 0.51% | 37 |
|
|
2018
Q2 | $967K | Hold |
10,432
| – | – | 0.52% | 34 |
|
|
2018
Q1 | $987K | Sell |
10,432
-950
| -8% | -$104K | 0.56% | 35 |
|
|
2017
Q4 | $1.1M | Hold |
11,382
| – | – | 0.58% | 38 |
|
|
2017
Q3 | $1.01M | Hold |
11,382
| – | – | 0.58% | 38 |
|
|
2017
Q2 | $825K | Hold |
11,382
| – | – | 0.5% | 41 |
|
|
2017
Q1 | $742K | Sell |
11,382
-323
| -3% | -$20.3K | 0.46% | 43 |
|
|
2016
Q4 | $733K | Sell |
11,705
-1,850
| -14% | -$113K | 0.49% | 42 |
|
|
2016
Q3 | $855K | Hold |
13,555
| – | – | 0.6% | 40 |
|
|
2016
Q2 | $839K | Sell |
13,555
-65,956
| -83% | -$4.02M | 0.59% | 38 |
|
|
2016
Q1 | $4.54M | Sell |
79,511
-1,250
| -2% | -$69.7K | 3.35% | 9 |
|
|
2015
Q4 | $4.78M | Sell |
80,761
-23
| -0% | -$1.32K | 3.4% | 7 |
|
|
2015
Q3 | $4.39M | Buy |
80,784
+13,694
| +20% | +$891K | 3.44% | 8 |
|
|
2015
Q2 | $4.51M | Buy |
67,090
+1,691
| +3% | +$110K | 3.61% | 5 |
|
|
2015
Q1 | $3.83M | Buy |
65,399
+4,827
| +8% | +$292K | 3.06% | 12 |
|
|
2014
Q4 | $3.96M | Buy |
60,572
+150
| +0.2% | +$9.46K | 3.47% | 7 |
|
|
2014
Q3 | $3.49M | Buy |
60,422
+2,050
| +4% | +$114K | 3.29% | 14 |
|
|
2014
Q2 | $3.29M | Buy |
58,372
+375
| +0.6% | +$19.7K | 3.07% | 15 |
|
|
2014
Q1 | $2.98M | Buy |
57,997
+1,800
| +3% | +$91K | 2.89% | 16 |
|
|
2013
Q4 | $2.97M | Buy |
+56,197
| New | +$2.76M | 2.87% | 16 |
|
Other funds holding ABBV
Crossvault Capital Management's ABBV Position: Q2 2022 in Review
Crossvault Capital Management reduced its AbbVie (ABBV) stake by 4.6% in Q2 2022, selling an estimated $655K and leaving 88,555 shares worth $13.6M. The position accounts for 5.34% of the portfolio, ranked #3.
Crossvault Capital Management first reported a position in ABBV in Q4 2013 and has held it in 35 quarters since. The position peaked at $15.1M in Q1 2022. 3,004 funds tracked by Wall St. Rank hold ABBV as of Q2 2022.
- Crossvault Capital Management held 88,555 shares of AbbVie worth $13.6M as of Q2 2022.
- Crossvault Capital Management sold 4,288 AbbVie shares in Q2 2022, an estimated $655K.
- AbbVie made up 5.34% of Crossvault Capital Management's portfolio in Q2 2022, its #3 holding.
- Crossvault Capital Management first reported a position in AbbVie in Q4 2013 and has held it in 35 quarters since.
- Crossvault Capital Management's AbbVie position peaked at $15.1M in Q1 2022.
- 3,004 funds tracked by Wall St. Rank held AbbVie as of Q2 2022.
Based on Crossvault Capital Management's 13F filing for Q2 2022, filed 8 Aug 2022.